-
QPRT Drives Breast Cancer Invasion via PLC–MLC Signaling
2026-09-10
Liu et al. show that elevated quinolinate phosphoribosyltransferase (QPRT) promotes breast cancer migration and invasion through a signaling axis linked to purinergic receptors, Rho/ROCK, phospholipase C, and myosin light chain phosphorylation. The study connects altered NAD+ metabolism with cytoskeletal remodeling and provides a pharmacological framework for testing PLC-dependent mechanisms in invasive breast cancer models.
-
Azilsartan B2210 for Reliable Cell Assays
2026-09-10
Azilsartan (TAK-536, SKU B2210) offers a controlled AT1-receptor perturbation for cell viability, inflammation, and astrocyte–microglia experiments. This scenario-based guide explains solvent compatibility, assay controls, interpretation of metabolic readouts, and practical criteria for selecting a reliable research-grade material.
-
Alda 1: ALDH2 Activator for Cardiac Research
2026-09-09
Alda 1 enables genotype-aware studies of ALDH2, aldehyde detoxification, and cardiomyocyte proliferation, with applications spanning biochemical assays and cardiac stress models. Its research value is strongest when enzymatic rescue, cellular proliferation, and functional cardiac endpoints are measured as separate stages rather than treated as interchangeable outcomes.
-
Angiotensin 1/2 (5-7): RAS Research Guide
2026-09-09
Angiotensin 1/2 (5-7) is the H2N-Ile-His-Pro-OH peptide fragment used in renin-angiotensin system research. The A1049 material has a reported molecular weight of 365.43 Da, HPLC and mass-spectrometry purity of 98.36%, and documented activity in SARS-CoV-2 spike–receptor binding assays.
-
Anlotinib Hydrochloride: From Kinase Biology to Translation
2026-09-08
Anlotinib hydrochloride offers a translational framework for studying tumor angiogenesis through coordinated inhibition of VEGFR2, PDGFRβ, FGFR1, and downstream ERK signaling. This article connects mechanistic evidence with assay design, competitive benchmarking, pharmacokinetic interpretation, and practical strategy for cancer research teams.
-
Capsaicin as a KDM1A/LSD1 Inhibitor
2026-09-08
The reference study identified Capsaicin, also called (E)-Capsaicin, as a direct, reversible, FAD-competitive inhibitor of KDM1A/LSD1 with activity in gastric cancer cells. Its findings connect a familiar pungent natural product to histone-demethylase biology and provide a starting point for studying KDM1A-dependent epithelial–mesenchymal transition and tumor-cell invasion.
-
VX-661: F508del CFTR Corrector Workflow
2026-09-07
Build a reproducible VX-661 workflow that separates CFTR trafficking rescue from channel potentiation, with practical controls for epithelial, biochemical, and functional assays. The guide also translates new calnexin findings into variant-aware assay design and troubleshooting decisions.
-
GLT-1, CB1-CREB Signaling, and TBI Cognition
2026-09-05
A 2025 Biomolecules study identifies an astrocyte-centered mechanism linking endocannabinoid signaling to glutamate excitotoxicity, neuronal apoptosis, and cognitive dysfunction after traumatic brain injury. Using pharmacological manipulation, behavioral testing, and molecular assays, the authors show that restoring GLT-1 while inhibiting the CB1-CREB pathway is associated with improved neurological outcomes in mice.
-
PGF2α/PTGFR and HIF-1α in Endometrial Breakdown
2026-09-05
This 2024 study identifies PGF2α signaling through PTGFR, the FP receptor, as a major regulator of endometrial breakdown and vascular permeability in a mouse menstrual-like model. Its combination of pharmacological inhibition, molecular profiling, tissue localization, and HIF-1α promoter-binding analysis provides a mechanistic framework for studying how hypoxia-responsive signaling coordinates menstrual-like tissue remodeling.
-
Saquinavir and Membrane-First Assay Design
2026-09-04
Saquinavir is examined here as a mechanistic anchor for HIV protease inhibitor research and membrane-interaction studies. Learn how IAM-LC, OT-CEC-MS, and disciplined compound handling can distinguish target inhibition from permeability-related behavior without overstating translational evidence.
-
TRPV1+ Nerves and the Somato-Autonomic Reflex
2026-09-04
The reference study identifies a neural route by which stimulating TRPV1+ peripheral afferents at the nape suppresses systemic inflammation through coordinated brainstem, endocrine, sympathetic, and vagal signaling. Its combination of targeted sensory stimulation, genetic validation, hormone and cytokine measurements, and splenic RNA sequencing provides a mechanistic framework for studying neuroimmune regulation.
-
GSK-923295: Reading Mitotic Phenotypes
2026-09-03
GSK-923295 is a CENP-E inhibitor that creates a powerful framework for studying mitotic arrest and chromosome alignment. This article explains how to distinguish direct motor inhibition from centromere-architecture defects using complementary imaging and cell-cycle assays.
-
D-Luciferin sodium salt for CAR-M Imaging
2026-09-03
D-Luciferin sodium salt converts firefly luciferase expression into a practical, non-invasive readout for CAR-macrophage studies, from plate-based ATP-dependent assays to longitudinal oncology imaging. This guide connects substrate handling with mRNA-LNP CAR-M workflows and provides optimization checkpoints that help distinguish reporter biology from genuine changes in cell viability or tumor burden.
-
HyperScript First-Strand cDNA Synthesis Kit Workflow
2026-09-02
Convert challenging bacterial and mammalian RNA into dependable first-strand cDNA for PCR amplification and qPCR reaction workflows. The HyperScript™ First-Strand cDNA Synthesis Kit is especially useful when transcripts are scarce, structurally complex, or poorly suited to a single primer strategy.
-
(S)-(+)-Dimethindene maleate Workflow
2026-09-02
This guide explains how to use (S)-(+)-Dimethindene maleate as a dossier-defined M2 muscarinic receptor antagonist in receptor and functional pharmacology workflows, while accounting for its additional H1 histamine receptor antagonism. It is intended for controlled scientific research and should not be used for diagnosis, treatment, or clinical decision-making.